Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $495 | $521 | $435 | $485 |
| - Cash | $93 | $95 | $58 | $83 |
| + Debt | $34 | $35 | $36 | $33 |
| Enterprise Value | $436 | $462 | $413 | $435 |
| Revenue | $300 | $302 | $279 | $266 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Gross Profit | $171 | $179 | $166 | $157 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| EBITDA | $59 | $51 | $13 | $53 |
| % Margin | 19.7% | 16.8% | 4.6% | 19.9% |
| Net Income | $36 | $27 | -$15 | $27 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS Diluted | 103.68 | 72.37 | -38.58 | 67.97 |
| % Growth | 43.3% | 287.6% | -156.8% | – |
| Operating Cash Flow | $61 | $73 | $37 | $46 |
| Capital Expenditures | -$7 | -$11 | -$25 | -$36 |
| Free Cash Flow | $54 | $62 | $13 | $10 |